<DOC>
	<DOCNO>NCT00189358</DOCNO>
	<brief_summary>Although initially responsive cytoreductive surgery platinum- and/or taxane-based chemotherapy , majority patient epithelial ovarian cancer , cancer fallopian tube peritoneum eventually relapse . Recurrence within 6 month complete platinum-containing chemotherapy indicate platinum-refractory cancer disease . New therapeutic strategy require platinum-refractory disease . Inhibition growth signal induce epidermal growth factor receptor pathway , estrogen receptor pathway provide promising target epithelial ovarian cancer , cancer fallopian tube peritoneum . The trial evaluate safety tolerability combination epidermal growth facto tyrosine kinase inhibitor ZD1839 clinically establish antiestrogen tamoxifen .</brief_summary>
	<brief_title>A Phase II Study ZD1839 Tamoxifen Patients With Epithelial Ovarian Carcinoma , Cancer Fallopian Tube Peritoneum Refractory Platinum- Taxane-based Therapy</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>histologically confirm epithelial ovarian cancer , cancer fallopian tube peritoneum refractory platinum taxanebased chemotherapy measurable nonmeasurable disease write informed consent age 18 year old Karnofsky performance status &gt; 60 % complete bowel obstruction symptomatic brain metastasis know hypersensitivity evaluate drug inadequate kidney function inadequate hepatic function evidence clinically active interstitial lung disease history congestive heart failure &gt; NYHA 2</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>cancer</keyword>
	<keyword>cancer alternative therapy</keyword>
	<keyword>ovarian cancer</keyword>
	<keyword>tyrosine kinase inhibitor</keyword>
</DOC>